GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Monte Rosa Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.66+0.92 (+9.45%)
Close on Oct 19, 2026
- Market cap
- $1.08B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-43.8%
Net margin
-31.2%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +63.5% | – | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 117.9% | -16.9% | |
| Return on assets | – | – | -8.7% | |
| Current ratio | – | 1.49 | 6.12 | |
| Capex to revenue | – | – | 3.8% | |
| Diluted shares | – | 2M | 83M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Monte Rosa Therapeutics generated $260.43M from operations and spent $50.37M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$260.43M
Used
$50.37M
Capital expenditure$50.37M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-31.2%
×Asset turnover0.28×
×Equity multiplier1.95×
=Return on equity, FY2025-16.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -31.2% | 0.28× | 1.95× | -16.9% |
| FY2024 | -96.1% | 0.20× | 1.85× | -36.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$38.60M
- Cash generatingOperating cash flow above zero-$22.80M
- Return on assets improvedROA up on the prior year-23.9% → -8.8%
- Earnings backed by cashOperating cash flow above net income-$22.80M vs -$38.60M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.40 → 6.12
- No dilutionShare count did not rise74M → 83M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.25 → 0.28